Abstract
Current guidelines lack sufficient evidence to recommend a specific blood pressure lowering strategy to prevent cardiovascular disease after preeclampsia. We conducted a double-blind cross-over trial to identify the most potent antihypertensive strategy: renin-angiotensin-aldosterone system (RAAS) inhibition (losartan), sympathoinhibition (moxonidine), low sodium diet and placebo (n = 10). Due to low inclusion rate our study stopped prematurely. Initiatory analyses showed no significant effect of antihypertensive strategy on office blood pressure and 24-hour blood pressure. However, nocturnal dipping was significantly higher on RAAS inhibition and low sodium diet compared to placebo and sympathoinhibition. Optimal cardiovascular prevention after preeclampsia should be further explored.
| Original language | English |
|---|---|
| Pages (from-to) | 173-175 |
| Number of pages | 3 |
| Journal | Pregnancy Hypertension |
| Volume | 27 |
| Early online date | 6 Jan 2022 |
| DOIs | |
| Publication status | Published - Mar 2022 |
Keywords
- Cross-over trial
- Hypertension
- Low sodium diet
- Postpartum
- Preeclampsia
- Renin-angiotensin-aldosterone system inhibition
- Sympathoinhibition